Pathophysiology of the obesity–kidney axis

• Obesity-related glomerulopathy is driven by adaptive glomerular hyperfiltration — the mechanism weight loss, RAAS blockade, and SGLT2 inhibition each unload, which makes it the clearest example of treating the obesity to treat the kidney.
• The therapeutic hinge: weight reduction (bariatric or GLP-1/GIP) can drive proteinuria into remission — a point where the biopsy read from nephrology and the weight-directed pharmacotherapy from obesity medicine combine to the patient’s benefit.
• Renal hemodynamics: single-nephron GFR, glomerular hypertension, RAAS and sympathetic activation.
• Adipokines (leptin, adiponectin, resistin), lipotoxicity, ectopic renal-sinus fat, tubular sodium retention.
• Uric-acid/fructose metabolism, the gut microbiome–bile-acid axis (FXR/TGR5), cellular senescence — evolving targets.
• Weight-loss–dependent vs proposed weight-loss–independent renoprotection of incretins (hemodynamic, natriuretic, anti-inflammatory) — the magnitude of the weight-independent component is still debated.
• Gene–environment risk (APOL1, monogenic obesity); the MASLD/MASH–CKD liver–kidney continuum.

Diagnosis and risk stratification

• Critiquing BMI; body-composition assessment (DXA, bioimpedance), visceral adiposity, sarcopenic obesity.
• Cystatin-C vs creatinine eGFR in obesity, including the CKD-EPI 2021 combined creatinine–cystatin C equation; BSA-indexing vs de-indexing for drug dosing; when to order measured GFR.
• Interpreting albuminuria in the setting of hyperfiltration — a “normal” eGFR can mask early nephron loss.
• ORG is routinely misclassified as diabetic nephropathy or hypertensive nephrosclerosis, so obesity as a primary, treatable kidney driver is missed — and naming it correctly redirects therapy toward weight loss alongside RAAS and SGLT2.
• The kidney biopsy is technically harder in obesity: greater skin-to-capsule distance, poorer ultrasound penetration, standard needles that may not reach the kidney, and higher rates of non-diagnostic cores and bleeding.
• Appraising emerging diagnostics: metabolomic/urinary-EV biomarkers, quantitative MRI fat, AI prediction — validated vs research-stage.

Pharmacotherapy and renal safety Core

• Renal evidence is agent- and endpoint-specific: semaglutide in FLOW (kidney-outcome trial); tirzepatide kidney data are exploratory/post-hoc (SURPASS-4, HR 0.58 [0.43–0.80]) — broader GLP-1 / dual-agonist renal evidence varies by agent and endpoint.
• Triple agonists (retatrutide): phase-2 post-hoc UACR/eGFR signals, the phase-2b renal-function study TRANSCEND-CKD (NCT05936151; iohexol mGFR, topline expected 2026), and the pivotal phase-3 outcomes trial TRIUMPH-Outcomes (NCT06383390; not before 2028–2029) — investigational; no reported phase-3 kidney-outcome results yet.
• Amylin analogs and combinations (cagrilintide, CagriSema); oral small molecules — renal PK, volume of distribution, electrolyte/acid–base effects.
• SGLT2 inhibitors cardiorenal effects; non-steroidal MRAs (finerenone; FIDELIO-DKD / FIGARO-DKD).
• The emerging multi-pillar model — RAAS blockade + SGLT2i + non-steroidal MRA + incretin — and rational sequencing in HFpEF, MASH, polypharmacy (not yet a guideline-codified protocol).
• Renal-safety surveillance: GI losses with GLP-1/GIP → hypokalemia, metabolic alkalosis, and prerenal AKI; topiramate metabolic acidosis; oxalate nephropathy after malabsorptive surgery.
• Bariatric metabolic sequelae: refeeding, thiamine deficiency, hypokalemia/-magnesemia/-calcemia, secondary hyperparathyroidism, vitamin-D deficiency.
• Deprescribing and the pharmacology of weight regain after discontinuation.

Nutrition & the protein dilemma

• Reconciling weight-loss and muscle-preservation goals with protein restriction in advanced CKD.
• Safety of very-low-calorie diets in CKD; generally avoid unsupervised ketogenic diets in advanced CKD; micronutrient load during active loss.
• Preventing sarcopenia; behavioral medicine — motivational interviewing, eating-disorder screening, weight stigma.
• Weight regain, maintenance, and nutrition after anti-obesity-drug discontinuation.

Metabolic & bariatric surgery

• Effects on albuminuria, eGFR trajectory, and CKD progression; surgery vs pharmacotherapy for renoprotection and transplant access.
• Candidate selection in CKD/ESKD; surgery as a bridge to listing.
• Endoscopic options (endoscopic sleeve gastroplasty) for high-risk patients unfit for surgery.
• Postoperative renal complications: oxalate nephropathy (particularly after malabsorptive procedures such as Roux-en-Y), nephrolithiasis, AKI; long-term stone/bone surveillance.

Transplantation

• Pre-listing: BMI cut-offs (many centers 35–40) restrict transplant access for people with obesity — an equity issue as much as a clinical one.
• Bridge to transplant: bariatric surgery (especially sleeve) — timing, altered immunosuppressant absorption after surgery, nutritional sequelae; GLP-1 RAs increasingly used for pre-listing weight reduction.
• Post-transplant: weight gain in the first year is the rule; PTDM/NODAT with obesity as the main risk factor, potentiated by tacrolimus and steroids.
• Recurrent or de-novo ORG in the graft; GLP-1 RAs in recipients — interactions with immunosuppression and safety are still-emerging areas of evidence.
• Immunosuppressant dosing in obesity (weight-based vs fixed, CNI pharmacokinetics); higher surgical complication rates.
• Living donation: the obese donor faces additive hyperfiltration — remnant-kidney plus obesity-driven — a specific risk to weigh.

Clinical deep-dives: Obesity in the transplant candidate · Post-transplant obesity and weight gain

The dialysis population

• Hemodialysis access: AVF creation is harder with deep vessels — higher primary failure, more need for superficialization/transposition, and difficult cannulation.
• Adequacy and the “V problem”: urea distribution volume vs body weight, and BSA- vs V-normalization of Kt/V — which weight to target for dose and drug dosing.
• The obesity survival paradox (higher BMI, better HD survival): must be understood — and muscle vs fat mass distinguished — to avoid mismanagement, not used as a blanket argument against treating obesity on RRT.
• Peritoneal dialysis — the sharpest nephro-obesity intersection: the glucose-based dialysate delivers a substantial calorie load, driving weight gain, hyperglycemia, dyslipidemia. Steer with icodextrin, prescription changes, and metabolic monitoring.
• PD catheter in a thick abdominal wall/omentum: higher leak, hernia, and exit-site risk; adequacy at large body volume.
• Intentional weight loss may be appropriate when needed for transplant access, mobility, metabolic complications, or PD mechanics; individualize for the HD or PD patient.

Clinical deep-dive: Obesity in the dialysis patient (HD & PD)

Special populations

• Pediatric obesity with CKD and transition to adult care.
• Monogenic/syndromic obesity with renal involvement (Bardet–Biedl, Alström); APOL1-related risk.
• Obesity, CKD, and preeclampsia in pregnancy; pre-conception considerations for incretins as safety data emerge.
• Geriatric sarcopenic obesity and frailty.
• The onco-nephrology interface: obesity is a shared risk factor for several cancers, and weight management, drug dosing, and AKI risk intersect in the CKD patient with cancer.

Stone and bone metabolism

• Obesity raises stone risk independently — especially uric-acid stones (low urine pH in insulin resistance), also calcium oxalate — tightly coupled to metabolic syndrome.
• The bariatric paradox: Roux-en-Y drives enteric hyperoxaluria → oxalate stones and oxalate nephropathy/CKD — a therapy for obesity that can, in this form, injure the kidney. Sleeve carries much less risk.
• Interpreting the 24-hour urine in metabolic context; how stone risk shifts during weight loss; CKD-MBD features specific to obesity and bone-health plans post-bariatric.

Integrated care, delivery & scholarship

• Designing a multidisciplinary cardio-renal-metabolic clinic around the CKM staging framework.
• Implementation science and health equity — access and cost of anti-obesity agents, disparities in underserved populations.
• Digital health (telemedicine, wearables, AI-assisted decision support — not yet validated for routine nephro-obesity care); pharmacovigilance (FAERS), registry and QI methods.
• Integrating guidance across the CKM guideline, KDIGO, and obesity-medicine boards.